Marco Sanduzzi Zamparelli

BCLC group, Liver Unit. Hospital Clínic of Barcelona. #ILCA GB Advisor

[Valerie Chew @Valeriechew29]

What a fun week at #EASL2026 in Barcelona! Great hanging up with the editorial team from @JHepatology and enjoying the outstanding MASLD-HCC session with my good friends @CancerInflam, @derekamann1 and @MarcoSanduzzi Also proud to support my PhD student's poster!

[Valerie Chew @Valeriechew29]

Early Sat am ☕️ at #EASL2026, but definitely worth waking up for exciting new data and discussions 💡 on “#MASLD-related #HCC: Pathogenesis, Immunology and Treatment” chaired by @CancerInflam and @MarcoSanduzzi
See you there!
@derekamann1 @EASLnews
https://t.co/huK8r4GzBN

[Jordi Bruix @bruixj]

Trial design is an evolving issue in which statisticians should be involved from time zero. Expert knowledge in all dimensions is key

[EASLnews @EASLnews]

The next Talk Liver to Me podcast drops tomorrow!! Here's a sneak-peek from this interactive discussion between @MattiasMandorf1, @MarcoSanduzzi and @LorenzaRimassa!

Read more: https://t.co/UoDXc82ud8

#LiverTwitter #LiverX

[ILCA @ILCAnews]

Present at #ILCA26 & share your latest research, receive feedback, spark new collaborations and most importantly contribute to the advancement of liver cancer care and research.
➡️Get started and submit before 13 April 2026: https://t.co/yjnZ0d8nkt

@QingheZeng @Valeriechew29

[ILCA @ILCAnews]

The call for abstracts is officially open for the ILCA Annual Conference and this is your moment to be where the science meets clinical practice.
Read more about the topics and submit your abstract before 13 April 2026: https://t.co/LshoBZZbfF

@docamitgs

[BCLC GROUP @BCLC_group]

Results of the GOING investigator initiated trial for 2nd line in HCC are already on-line. We tested a sequential add-on strategy rather than two drugs from star. Encouraging response rate while preserving safety. https://t.co/85MMPzlUVl
@hospitalclinic @idibaps @ContraCancerEs

[Jordi Bruix @bruixj]

Here the link to the BCLC 2025 model https://t.co/PNiwgOP8M8. The CUSE approach informs options to consider according to strength of evidence. Individualized decision making with patient involvement. @hospitalclinic @ILCAnews @ContraCancerEs @EASLnews

[BCLC GROUP @BCLC_group]

Great informative talk by @MarcoSanduzzi about future prospects of systemic treatment for HCC at the @AEEHLiver PGC. Experience + knowledge @hospitalclinic @idibaps @ContraCancerEs

[ILCA @ILCAnews]

If you haven't heard yet, the ILCA Annual Conference is coming back to Europe this year and we’ll meet in Brussels, 3-5 Sept. !
Keep an eye out for more updates and the #ILCA26 abstract submission opening soon.
https://t.co/KHIrfJrBUM
For now, let’s look back at #ILCA25 📸

[ILCA @ILCAnews]

It’s official – #ILCA26 is returning to Europe!
Join us in Brussels, Belgium, on 3–5 September 2026 for three days of insights into the latest in #livercancer research.
@StephenLChan1 @docamitgs @Valeriechew29 @LorenzaRimassa @AnjanaPillaiMD @siadaniela @allaire_manon

[Jordi Bruix @bruixj]

A webinar to comment the Lancet Commission paper about liver cancer takes place on Thursday. We will comment geographic differences to be solved in order to secure access to effective treatments, as well as research challenges to be tackled .
link https://t.co/CiV0fYndtQ

[ILCA @ILCAnews]

Recent advances in liver cancer treatment have brought new hope to patients worldwide. But progress is also about making care more personal with tailored treatment approaches that match each patient’s unique needs. 💚

#LiverCancerAwarenessMonth

[Maria Varela @Maria_Var_Cal]

Representación del Comité Multidisciplinar de Cáncer de Hígado de @HUCA_Asturias en BCLC UPDATE by @BCLC_group

Volvemos cargados de energía e ilusión.

Gracias @ma5RN por tu excelente organización ❤️❤️

Nos vemos en 2026!!!!

[IDIBAPS @idibaps]

🆕The Hepatic Oncology Research Group @BCLC_group has published the new version of the guidelines for the management of hepatocellular carcinoma, the most common primary liver cancer

These guidelines present a new model for personalizing treatment

👉https://t.co/AMNbBAzXUb

[BCLC GROUP @BCLC_group]

The BCLC 2025 model for prognosis and treatment recommendation is available in press. https://t.co/xmSI9l6hoG
In brief, it will be presented by @ma5RN with introduction of the CUSE concept https://t.co/eTbhfLufoL Major relevance for clinical decision making @hospitalclinic

[BCLC GROUP @BCLC_group]

The presentation takes place. Full room!!

[BCLC GROUP @BCLC_group]

The BCLC 2025 update starts next Monday. We will have full room but virtual attendance is available. Worth to see the launch of the updated BCLC prognostic and treatment model for HCC @hospitalclinic @AEEHLiver @ILCAnews @EASLnews @AASLDtweets @ContraCancerEs @idibaps

[BCLC GROUP @BCLC_group]

Nice involvement of @MarcoSanduzzi at the @aeeh translational meeting in Pamplona. Great recruit into the BCLC! @hospitalclinic @idibaps @ContraCancerEs

[Maria Varela @Maria_Var_Cal]

@SilviaAffo @AEEHLiver @ContraCancerEs @FundacionFero @atuvibi Mesa redonda sobre la “Participación ciudadana en la Investigación.”

📍Informar y educar a los pacientes y a la sociedad
📍Visibilizar el cáncer de hígado
📍Involucrar a los pacientes en el diseño de los estudios y en la evaluación de los proyectos